3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
3-Deazauridine (NSC 126849) is a structural analog of uridine that inhibits the biosynthesis of Cytidine-5'-Triphosphate by competitive inhibition of Cytidine Triphosphate synthetase which is considered to be the primary mode of action of this nucleoside analog. Despite a paucity of clinical attention given to this drug as a single agent, it has generated much enthusiasm as a biological response modulator because of its synergistic effect with a number of antitumor agents including Cytosine Arabinoside, 5-aza-2'-deoxycytidine, 5-azacytidine, thymidine and D-galactosamine, although only the cytosine arabinoside/3-Deazauridine combination has been explored clinically. In this paper, the current status of the drug and future perspectives will be discussed.
W J
WJ
Moriconi
M
M
Slavik
S
S
Taylor
D015092:3-Deazauridine / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000208:Acute Disease; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D000077209:Decitabine; D004341:Drug Evaluation; D004357:Drug Synergism; D005688:Galactosamine / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D013936:Thymidine / Q000494:pharmacology; D014529:Uridine / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D003561:Cytarabine; D015092:3-Deazauridine; D005688:Galactosamine; D000077209:Decitabine; D001374:Azacitidine; D013936:Thymidine; D014529:Uridine